文献速递临床试验与 GCP

MyoCare在欧洲的临床评估(CEME):一项前瞻性、多中心、随机、双盲、对照临床试验的研究方案

Clinical Evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial.
PubMed 文献 · Trials · 2023-10-17

本研究为一项为期2年的前瞻性、多中心、随机、双盲、对照临床试验,计划招募300名6至13岁欧洲儿童,随机分为佩戴MyoCare镜片的研究组(150名)和佩戴Clearview镜片的对照组(150名),主要比较两组球镜等效屈光度的年均进展,次要结局包括眼轴长度、脉络膜厚度、隐斜和调节状态,旨在评估基于同时竞争性离焦设计的新型眼镜片在欧洲儿童中的近视控制疗效。

要点

  • 拟招募300名6至13岁近视儿童,随机分组佩戴MyoCare或Clearview眼镜片。
  • 主要结局为比较两组球镜等效屈光度的年均进展。
  • 次要结局包括眼轴长度、脉络膜厚度、隐斜和调节状态。

核心结论

  • 本研究将是欧洲儿童中首个基于同时竞争性离焦设计的眼镜片的随机对照临床试验,结果将揭示该新设计眼镜片在非亚洲人群中近视管理的疗效临床证据。

研究设计与样本

  • 为期2年的前瞻性、多中心、随机、双盲、对照临床试验,计划招募300名6至13岁儿童,随机分为研究组(150名,佩戴MyoCare)和对照组(150名,佩戴Clearview)。
  • 纳入标准为球镜等效屈光度在-0.75D至-5.00D之间、散光<1.50D、屈光参差<1.00D,且既往进展至少-0.50D。

主要发现

  • 主要结局为比较两组球镜等效屈光度的年均进展。
  • 次要结局为两组的眼轴长度、脉络膜厚度、隐斜和调节状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myopia prevalence has been increasing in the last decades, and its pathological consequences, including myopic maculopathy and high myopia-associated optic neuropathy, are now one of the most common causes of visual impairment. It is estimated that by 2050, more than 50% of Europeans and Americans will be myopes, which is alarming due to the high morbidity of myopes over - 6.00D. Once myopia has appeared, there are different options with scientific evidence to try to slow the axial length growth. Ophthalmic lenses are the less invasive treatment to control myopia, and there is evidence about the efficacy of different designs, mainly in the Asiatic population. However, new designs have been launched, and it is not known if efficacy is the same between Asiatic and European subjects. Thus, we have set up a randomized, controlled, double-blind, and multicenter trial to investigate the efficacy of a new design of ophthalmic lenses for myopia control in European children. METHODS: A 2-year prospective, multicenter, randomized controlled, and double-blind clinical trial is used to investigate the efficacy of a new design of ophthalmic lenses to slow the progression of myopia. Three hundred children aged from 6 to 13 years old will be recruited and randomly assigned to a study or control group. The study group will be composed of 150 children wearing MyoCare while the control group will be composed of 150 children wearing Clearview. The inclusion criteria will be myopia with a spherical equivalent between - 0.75D and - 5.00D, astigmatism < 1.50D, and anisometropia < 1.00D and having a historical evolution of at least - 0.50 The primary outcome is to compare the mean annual progression of the spherical equivalent between both groups. The secondary outcomes are axial length, choroidal thickness, phorias, and accommodative status of both groups. DISCUSSION: This study will be the first randomized and controlled clinical trial in European children with spectacle lenses based on simultaneous competing defocus. The results will shed light on the clinical evidence of spectacle lenses relying on this new design for the management of myopia with results of efficacy in the non-Asiatic population. TRIAL REGISTRATION: EU Clinical Trials Register (EudraCT) 2022-001696. Registered on 27 April 2022. CLINICALTRIALS: gov NCT05919654. Registered on 26 June 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Alvarez-Peregrina C, Sanchez-Tena MA, Martinez-Perez C, et al. Clinical Evaluation of MyoCare in Europe (CEME): study protocol for a prospective, multicenter, randomized, double-blinded, and controlled clinical trial. Trials. 2023. PMID: 37848908. doi:10.1186/s13063-023-07696-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。